Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Class I antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

It is very uncertain whether class III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 0.96 [0.06, 15.5]
1 study · 212 participants
Very low

Class I and/or III antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 0.96 [0.06, 15.5]
1 study · 212 participants
Very low